Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

Inclusion Criteria:

1. Male or female, aged 18-75 years (including 18 and 75 years old)；

2. Patients with relapsed glioblastoma, as confirmed by positron emission tomography (PET) or histologic pathology；

3. A >= 30% staining extent of B7-H3 in his/her primary/recurrent tumor tissue by theimmunochemical method;

4. Karnofsky scale score>=50

5. Availability in collecting peripheral blood mononuclear cells (PBMCs) ；

6. Adequate laboratory values and adequate organ function;

7. Patients with childbearing/fathering potential must agree to use highly effectivecontraception；

Exclusion Criteria:

1. Pregnant or breastfeeding females；

2. Contraindication to bevacizumab；

3. Within 5 days before the CAR-T cell infusion, subjects receiving systemicadministration of steroids with dosage more than 10mg/d prednisone or the equivalentdoses of other steroids ( not including inhaled corticosteroid)；

4. Comorbid with Other uncontrolled malignancy；

5. Active immunodeficiency virus (HIV) or hepatitis B virus or hepatitis C virus ortuberculosis infection;

6. Subjects receiving the placement of a carmustine slow-release wafer within 6 monthsbefore the enrollment;

7. Autoimmune diseases;

8. Receiving long-term immunosuppressive treatment after organ transplantation;

9. Severe or uncontrolled psychiatric diseases or condition that could increase adverseevents or interfere the evaluation of outcomes;

10. Not recovered from the toxicities or side effects by previous treatment;

11. Subjects who have participated the other interventional trial within one monthbefore the enrollment, or have received other CAR-T cell therapies or gene-modifiedcell therapy before enrollment.

12. Subjects with medical conditions that affect signing the written informed consent orcomplying with the research procedures, the medical conditions including, but notlimited to cardio-cerebral vascular diseases, renal dysfunction/failure, pulmonaryembolism, coagulation disorders, active systemic infection, uncontrolled infectionet. al; or patients who are unwilling or unable to comply with the researchprocedures; these

13. Subjects with other conditions that would interfere trial participation at theinvestigator's discretion.